If you tell a scientist that they should be growing a spine, they might take you literally. For instance, if you say this because you want a scientist to show some courage and speak out about something difficult, instead they might try to make an actual human spine in a lab. We’ll start there this […]
Weekly reads: grow a spine, China clears MSCs, Denise Richards, stem cell soups Read More »
The private cord blood bank industry has promised families all kinds of great things over the years. A typical ad for such cord blood banks might say, “Your child may need cord blood in the future for a cure.” The industry also often uses the analogy of frozen cord blood as an insurance policy for
The New York Times just broke a story on Burst Biologics and Weill Cornell that fits with long-standing troubling questions about regenerative biologics producers. The story also bears on the doctors and hospitals like Weill Cornell that were or are customers of the suppliers. Further, what is the FDA’s role in all of this? The
Burst Biologics unapproved biologic used by Weill Cornell: was there a cover-up? Read More »
Retraction Watch has been a great resource for those of us who have been following research misconduct. They widely cover and conduct research on retractions, corrections, and other developments in this space. Unfortunately, there’s been plenty to write about even just within the stem cell and cell therapy arena, which is my primary interest. Think
I’ve been more interested in histones and their modifications versus DNA methylation when it comes to epigenetics and chromatin. In part this has just been because I have studied histones so much more. For example, we have been knocking out the two histone variant H3.3 genes, H3f3a and H3f3b, now for a decade. My lab also
Weekly reads: DNA methylation, H3 K27M in glioma, memory wipe, teeth Read More »
It’s a big challenge to get a cell therapy approved by the FDA and if you look at my list of FDA-approved stem cell therapies, it’s not as long as we might hope. FDA OK on cell therapy from Gamida Cell For this reason, it was excellent news to see that the FDA approved a
Weekly reads: FDA nod on new cell therapy, gray hair, pong-playing cells Read More »
It’s been almost seventeen years that I’ve been a professor here at UC Davis Medical School. It feels like home. I enjoy teaching our first-year medical students each year. Some end up doing research in my lab. Our school recently got a nice write-up over at STAT News by Usha Lee McFarling on the diversity
Weekly reads: UC Davis Medical School diversity, CRISPR, Parkinson’s Read More »
Someday could human brain organoids get to the point of having organized human-like thoughts? Even consciousness? The more time passes, the less likely I think this is. It’s not impossible, but brain organoids have big limitations in that regard. To be clear, I don’t mean brain organoids having some vaguely human brain-like electrical activity. Even monolayers of
Stem cell research ethics topics: organoid consciousness & embryo models Read More »
Imagine writing or editing an article for the WaPo about risky, unproven medical interventions for COVID that desperate patients might consider. Then you link directly to the websites selling this stuff in your article. What the heck? WaPo links to risky long COVID “treatments” By linking, you not only are driving customers to these firms,
Weekend reads: WaPo blows it on COVID, paper-mill detector, adult pluripotent stem cells Read More »
The big news of the week was the big FDA stem cell in court by Judge Jesus Bernal here in California, who ruled in favor of a chain of stem cell clinics called Cell Surgical Network. The FDA had been seeking an injunction against the clinics. I believe the ruling was founded in part on
Weekly reads: CRISPR, FDA stem cell loss, pioneering AMD study, MS, Verve Therapeutics Read More »